Pooled RCTs: Atorvastatin did not increase renal-related serious adverse events

Pooled RCTs: Atorvastatin did not increase renal-related serious adverse events

Bibliographic Details
Main Authors:	Herrington, W, Haynes, R
Format:	Journal article
Published:	2014

Similar Items

Did the effect of placebo increase in rcts of panic disorder across the years?
by: F. Di Segni, et al.
Published: (2021-04-01)

COVID-19 Vaccination Did Not Increase the Risk of Potentially Related Serious Adverse Events: 18-Month Cohort Study in an Italian Province
by: Maria Elena Flacco, et al.
Published: (2022-12-01)

Serious Neurological Adverse Events of Ceftriaxone
by: Clémence Lacroix, et al.
Published: (2021-05-01)

Study title: A systematic review of RCTs to examine the risk of adverse cardiovascular events with nicotine use
by: Mimi M. Kim, et al.
Published: (2023-03-01)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
by: Bin Zhao, et al.
Published: (2018-10-01)

Central adjudication of serious adverse events did not affect trial's safety results: Data from the Efficacy of Nitric Oxide in Stroke (ENOS) trial.
by: Peter J Godolphin, et al.
Published: (2018-01-01)

Essay 3. RCTs and relational efficacy
by: Schwartz, L
Published: (2017)

Analysis of serious adverse event: Writing a narrative
by: Indu Nambiar
Published: (2018-01-01)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
by: Bin Zhao, et al.
Published: (2019-01-01)

Electronic self-reporting of adverse events for patients undergoing cancer treatment: the eRAPID research programme including two RCTs
by: Galina Velikova, et al.
Published: (2022-02-01)

Calculation of NNTs in RCTs with time-to-event outcomes: A literature review
by: Vervölgyi Elke, et al.
Published: (2009-03-01)

Vocal music enhances memory and language recovery after stroke: pooled results from two RCTs
by: Aleksi J. Sihvonen, et al.
Published: (2020-11-01)

Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System
by: Matthew S. Duprey, et al.
Published: (2019-08-01)

Embedding surveillance into clinical care to detect serious adverse events in pregnancy
by: Seale, A, et al.
Published: (2015)

Acetazolamide induced noncardiogenic pulmonary edema, an underreported serious adverse event
by: Andrew H. Schwartz, et al.
Published: (2023-06-01)

A Cancer Patient’s Experience With a Rare But Serious Adverse Event
by: Amlan RayChaudhury PhD
Published: (2020-08-01)

The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs
by: Barrington Keith J
Published: (2001-02-01)

UNDERSTANDING THE USES AND LIMITATIONS OF RCTS
by: Baigent, C
Published: (2009)

Critically appraised paper: In adults receiving intensive care, increased early active mobilisation did not improve clinical outcomes but increased adverse events
by: Vinicius Cavalheri
Published: (2023-01-01)

Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial
by: Elizabeth C. James, et al.
Published: (2020-09-01)

Depression and anxiety in cancer patient enrolled in clinical trials with serious adverse events
by: Zhen Peng, et al.
Published: (2023-10-01)

Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors
by: Xiujin Chen, et al.
Published: (2022-12-01)

Serious adverse event: late neurotropic disease associated with yellow fever vaccine
by: Henrique Souza Barros de Oliveira, et al.
Published: (2020-02-01)

Atorvastatin increases fear processing in healthy participants
by: Martens, M, et al.
Published: (2020)

The use of healthcare systems data for RCTs
by: Alice-Maria Toader, et al.
Published: (2024-01-01)

Realist RCTs of complex interventions - an oxymoron.
by: Marchal, B, et al.
Published: (2013)

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
by: Abdul Rafeh Naqash, et al.
Published: (2019-07-01)

Critically appraised paper: In adults receiving intensive care, increased early active mobilisation did not improve clinical outcomes but increased adverse events [commentary]
by: Michelle E Kho
Published: (2023-01-01)

The Shiny Balancer - software and imbalance criteria for optimally balanced treatment allocation in small RCTs and cRCTs
by: Thomas Grischott
Published: (2018-10-01)

Prevalence rate of spontaneously reported adverse events and determinants of serious adverse events amongst three outpatient care settings in ghana: findings and implications
by: Israel Abebrese Sefah, et al.
Published: (2021-01-01)

Exploring procedure duration and risk for serious adverse events during congenital cardiac catheterization
by: Lisa Bergersen, et al.
Published: (2023-06-01)

Associations of High‐Sensitivity Troponin and Natriuretic Peptide Levels With Serious Adverse Events in SPRINT
by: Simon B. Ascher, et al.
Published: (2022-03-01)

Cardiotoxicity of FDA-approved immune checkpoint inhibitors: A rare but serious adverse event
by: Abdulrazzak Zarifa, et al.
Published: (2018-10-01)

The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
by: Hou H, et al.
Published: (2019-05-01)

RCTs, Mahatma Gandhi and Public Health
by: Singh AJ
Published: (2004-01-01)

Analysis of adverse events of renal impairment related to platinum-based compounds using the Japanese Adverse Drug Event Report database
by: Misa Naganuma, et al.
Published: (2018-04-01)

Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review
by: Martin Underwood, et al.
Published: (2024-04-01)

Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis
by: Singh-Phulgenda, S, et al.
Published: (2021)

The association between antihypertensive treatment and serious adverse events by age and frailty: a cohort study
by: Sheppard, JP, et al.
Published: (2023)

Pathological Complete Response to Pembrolizumab plus Axitinib Combination following Serious Immune-Related Adverse Events in an Advanced Renal Cell Carcinoma Patient with a History of Rheumatoid Arthritis
by: Marco Bergamini, et al.
Published: (2024-01-01)